Tripenem powder for injection

Dexa Medica

Ingredients in every vial

Meropenem 1000 mg

Each package contains

1 vial of 1 g

Other details

Dosage form:Powder for Injection
Flavour None

W.H.O. classification

ATC Level 1 J - Antiinfectives for systemic use
ATC Level 2 J01 - Antibacterials for Systemic Use
ATC Level 3 J01D - Other Beta-Lactam Antibacterials in ATC

Warnings

Pregnancy

CAUTIONThis item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.

Lactation

CAUTIONThis item may not be safe for use during lactation. Use with caution and after consultation with your doctor.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in

Indonesia
Myanmar
Cambodia

Dosage information

18 TO 65 YEARS OLD
The dosage and duration of therapy shall be established depending on type and severity of infection and the condition of the patients.
The recommended daily dosage is as follows:
– Treatment of pneumonia, UTI, gynecological infections such as endometritis, skin and skin structure infections: 500 mg IV every 8 hours.
– Treatment of nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients, septicemia: 1 g IV every 8 hours.
– In meningitis the recommended dosage is 2 g every 8 hours.

As with other antibiotics, particular caution is recommended in using meropenem as monotherapy in critically ill patients with known or suspected Pseudomonas aeruginosa, lower respiratory tract infection. Regular sensitivity testing is recommended when treating Pseudomonas aeruginosa infection.

12 TO 18 YEARS OLD
The dosage and duration of therapy shall be established depending on type and severity of infection and the condition of the patients.
The recommended daily dosage is as follows:
– Treatment of pneumonia, UTI, gynecological infections such as endometritis, skin and skin structure infections: 500 mg IV every 8 hours.
– Treatment of nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients, septicemia: 1 g IV every 8 hours.
– In meningitis the recommended dosage is 2 g every 8 hours.

As with other antibiotics, particular caution is recommended in using meropenem as monotherapy in critically ill patients with known or suspected Pseudomonas aeruginosa, lower respiratory tract infection. Regular sensitivity testing is recommended when treating Pseudomonas aeruginosa infection.

0 TO 12 YEARS OLD
For children over 3 months-12 years of age:
the recommended dose is 10 to 20 mg/kg every 8 hours depending on the type and severity of infection, susceptibility of the pathogen and the condition of the patient. In children over 50 kg weight, adult dosage should be used.

In meningitis the recommended dose is 40 mg/kg every 8 hours. There is no experience in children with renal impairment.

65 YEARS OLD AND ABOVE
No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/minute.

IMPAIRED RENAL FUNCTION
Dosage should be reduced in patients with creatinine clearance less than 51 ml/minute.

HEPATIC INSUFFICIENCY
No dosage adjustment is necessary in patients with hepatic insufficiency.

Indication

Meropenem trihydrate is indicated as a single agent therapy in Adults and children, for the treatment of the following infections caused by single or multiple susceptible strains of the designated microorganisms sensitive to meropenem:
– pneumonias and nosocomial pneumonias,
– urinary tract infections (UTI),
– intra-abdominal infections,
– gynecological infections, such as endometritis,
– skin and skin structure infections,
– meningitis,
– septicemia,
– empiric treatment, for presumed infections in Adults patients with febrile neutropenia, used as monotherapy or in combination with antiviral or antifungal agents.

Meropenem trihydrate has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections.

There is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.